Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.40 |
| ▸ | ACACA | Q13085 | 2/20 | 0.37 |
| ▸ | TLR4 | O00206 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2209619 | 0.84 | DUT (0.41) | DUTFFAR1MAOAMAOB | |
| SCHEMBL4085382 | 0.84 | DUT (0.41) | DUTFFAR1MAOAMAOB | |
| SCHEMBL17024422 | 0.83 | DUT (0.42) | DUTACACAACACBFFAR1 | |
| SCHEMBL2205493 | 0.83 | DUT (0.42) | DUTACACAACACBFFAR1 | |
| SCHEMBL4568785 | 0.79 | TLR4 (0.43) | ACACATLR4TLR2ACACBFFAR1 | |
| SCHEMBL4568808 | 0.79 | TLR4 (0.43) | ACACATLR4TLR2ACACBFFAR1 | |
| SCHEMBL4568981 | 0.79 | TLR4 (0.43) | ACACATLR4TLR2ACACBFFAR1 | |
| SCHEMBL4568827 | 0.79 | TLR4 (0.43) | ACACATLR4TLR2ACACBFFAR1 | |
| SCHEMBL4568784 | 0.79 | TLR4 (0.43) | ACACATLR4TLR2ACACBFFAR1 | |
| SCHEMBL8902105 | 0.78 | SIRT2 (0.43) | TLR4TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190183816-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183816-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | DUT 3010/4885ACACA 229/4885TLR4 595/4885 |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | DUT 3010/4885ACACA 229/4885TLR4 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.